8-K: MIRA Initiates MAD Phase 1 for Ketamir-2, Targets CIPN

MIRA Pharmaceuticals has initiated the multiple ascending dose portion of its Phase 1 study for oral Ketamir-2 and selected chemotherapy-induced neuropathic pain as its lead Phase 2a indication.

Summary

• MIRA Pharmaceuticals initiated the Multiple Ascending Dose (MAD) portion of its Phase 1 clinical trial for oral Ketamir-2 in healthy volunteers.
• Chemotherapy-induced peripheral neuropathy (CIPN) has been selected as the lead indication for the planned Phase 2a clinical evaluation.
• The Single Ascending Dose (SAD) portion of the study completed dosing with no serious or dose-limiting adverse events and no clinically significant safety concerns.
• The MAD portion involves three cohorts with repeat daily oral dosing of Ketamir-2, ranging from 150 mg to 600 mg, for five days.
• Preclinical studies showed Ketamir-2 outperformed ketamine, gabapentin, and pregabalin in reducing pain behaviors and restoring sensory function in neuropathic pain models.
• In a paclitaxel chemotherapy-induced neuropathy model, Ketamir-2 achieved near complete normalization of pain sensitivity and demonstrated greater efficacy than gabapentin.
• Ketamir-2 is a novel, non-scheduled oral ketamine analog designed for once-daily dosing without hallucinogenic or dissociative effects, addressing limitations of traditional ketamine.

Sentiment

Score: 8

Explanation: The filing reports significant positive progress in a clinical trial, including successful completion of the SAD phase with no safety concerns, initiation of the MAD phase, and selection of a high-need indication with strong preclinical data and potential for Fast Track designation. This indicates strong momentum and positive prospects for the drug candidate.

Positives

• Successful completion of the Single Ascending Dose (SAD) portion of the Phase 1 study with no serious or dose-limiting adverse events and no clinically significant safety concerns.
• Initiation of the Multiple Ascending Dose (MAD) portion of the Phase 1 study, indicating progress in clinical development.
• Selection of Chemotherapy-Induced Peripheral Neuropathy (CIPN) as the lead Phase 2a indication, addressing a significant unmet medical need with no FDA-approved treatments.
• Strong preclinical data demonstrating Ketamir-2's superior efficacy compared to ketamine, gabapentin, and pregabalin in neuropathic pain models, including near complete normalization of pain sensitivity in a CIPN model.
• Ketamir-2's profile as a novel, non-scheduled oral analog of ketamine with good oral absorption, once-daily dosing, and absence of hallucinogenic or dissociative effects, addressing key limitations of ketamine.
• Potential for regulatory incentives such as FDA Fast Track designation due to the significant unmet medical need in CIPN.

Risks

• Comprehensive pharmacokinetic analyses will be performed following unblinding, meaning the full PK profile is not yet publicly characterized.
• Further development is required for Ketamir-2 as a potential non-opioid therapy, implying future clinical and regulatory hurdles.
• Clinical trials inherently carry risks of unexpected adverse events or lack of efficacy in human subjects, despite positive preclinical and early Phase 1 SAD data.

Future Outlook

MIRA Pharmaceuticals plans to advance Ketamir-2 toward Phase 2a clinical evaluation for chemotherapy-induced neuropathic pain, a condition with no approved treatments. The company believes Ketamir-2 may qualify for FDA Fast Track consideration due to the significant unmet medical need.

Management Comments

• We have initiated the multiple ascending dose (MAD) portion of our ongoing Phase 1 clinical trial, evaluating our lead oral candidate, Ketamir-2, in healthy volunteers.
• We have selected chemotherapy-induced peripheral neuropathy (CIPN) as the lead indication for our planned Phase 2a clinical evaluation.
• We believe that Ketamir-2s pharmacologic profile and preclinical results support its further development as a potential non-opioid therapy for this indication.
• Given the absence of FDA-approved treatments for chemotherapy-induced neuropathic pain and the significant medical unmet need in oncology supportive care, we believe Ketamir-2 may qualify for consideration of regulatory incentives such as Fast Track designation.

Industry Context

Chemotherapy-induced peripheral neuropathy (CIPN) represents a significant and widespread challenge in oncology, affecting a large percentage of cancer patients with persistent pain and impacting quality of life. Despite its prevalence, there are currently no FDA-approved therapies for CIPN, highlighting a critical unmet medical need. MIRA Pharmaceuticals' advancement of Ketamir-2 as a potential non-opioid treatment directly addresses this gap, positioning it in a high-demand area within supportive cancer care and pain management.

Comparison to Industry Standards

• Ketamir-2 outperformed ketamine, gabapentin, and pregabalin in preclinical neuropathic pain models, demonstrating superior efficacy.
• In the paclitaxel chemotherapy-induced neuropathy model, Ketamir-2 produced near complete normalization of pain sensitivity, showing greater efficacy than gabapentin, an FDA-approved standard for neuropathic pain.
• Unlike traditional ketamine, Ketamir-2 is an oral analog designed for once-daily dosing without hallucinogenic or dissociative effects, addressing key limitations of existing ketamine use.
• The absence of FDA-approved treatments for CIPN positions Ketamir-2 to potentially fill a significant void where current standards of care are inadequate or non-existent.

Stakeholder Impact

• Shareholders: Positive impact due to significant progress in drug development, successful early-stage clinical trial results, and targeting a high-value indication with unmet medical need, potentially increasing company valuation.
• Patients (with CIPN): Potential for a novel, non-opioid treatment option for a debilitating condition with no approved therapies, offering hope for improved quality of life.
• Healthcare Providers: Potential for a new therapeutic tool to manage chemotherapy-induced neuropathic pain, addressing a current treatment gap.
• Employees: Positive impact from successful R&D milestones, potentially boosting morale and job security.

Next Steps

• Perform comprehensive pharmacokinetic analyses following unblinding of the SAD and MAD data.
• Advance Ketamir-2 towards Phase 2a clinical evaluation for chemotherapy-induced peripheral neuropathy (CIPN).
• Pursue potential regulatory incentives such as FDA Fast Track designation for Ketamir-2 in CIPN.

Key Dates

Recommendation

The filing details significant positive advancements for MIRA Pharmaceuticals' lead candidate, Ketamir-2. The successful completion of the SAD Phase 1 study with a clean safety profile and the initiation of the MAD phase de-risk the early clinical development. The selection of Chemotherapy-Induced Peripheral Neuropathy (CIPN) as the lead indication is highly strategic, as it represents a large market with a critical unmet medical need and no FDA-approved treatments, offering a clear path for potential FDA Fast Track designation. The strong preclinical data, showing superiority over existing treatments like gabapentin, further bolsters the drug's potential. These milestones collectively indicate strong clinical and commercial prospects, making the stock a 'strong buy' for investors seeking exposure to innovative pain management solutions.

Keywords

MIRA Pharmaceuticals, Ketamir-2, Phase 1 Clinical Trial, Multiple Ascending Dose, Chemotherapy-Induced Peripheral Neuropathy, CIPN, Neuropathic Pain, Non-opioid, FDA Fast Track, Drug Development, Biotechnology, Clinical Study